日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

China becomes key strategic market for CSL

By ZHOU WENTING in Shanghai | China Daily | Updated: 2025-12-18 09:08
Share
Share - WeChat

Australian biopharmaceutical company CSL has designated China as one of its most important strategic markets worldwide, a milestone highlighted by a significant expansion of both its workforce and investment in the country, said a senior executive.

Since 1986, CSL — a century-old firm — has supplied human albumin to Chinese patients, with a large proportion of the company's albumin products supplied to the China market. According to data released by information consultancy IQVIA in September, CSL's human albumin has maintained the largest market share in China.

Wang Yu, general manager of CSL China

"As the world's second-largest pharmaceutical market, China, a market that we've been deeply involved with for 40 years, is a critical growth engine within CSL's global blueprint," said Wang Yu, general manager of CSL China, during a recent interview in Shanghai.

"Looking ahead at the vast market potential and opportunities, CSL will focus on 'new products, new collaborations, and new efficiency', driving sustainable and high-quality growth," she said.

For four decades, CSL has been committed to addressing the needs of patients with rare and severe diseases in China.

Human albumin, derived from human plasma, is used clinically for emergency treatment of hypovolemia, severe hypo-albuminemia, neonatal hyperbilirubinemia, and acute respiratory distress syndrome, among others.

Since 2018, CSL has experienced significant growth in China, according to Wang. Within regulatory limits, the company has supported medical institutions and clinical experts, contributing to the publication of several treatment guidelines and consensus documents, thus advancing the standardization and rational use of human albumin in the country.

In response to the Guangdong-Hong Kong-Macao Greater Bay Area's special access policy for Hong Kong and Macao drugs and medical devices that allows designated hospitals in the bay area to use Hong Kong-approved drugs and medical devices, CSL has facilitated the introduction of anti-D immunoglobulin to three medical institutions on the Chinese mainland, benefiting over 3,000 pregnant women with rare Rh-negative blood.

In March, Paul McKenzie, CEO and managing director of CSL, emphasized at the China Development Forum that China is a crucial strategic market for the company. He reiterated the company's commitment to deepening its presence in China, and fostering innovation with upstream and downstream partners to support the development of China's healthcare sector.

"The strategic market designation of China together with other markets, such as the United States and Germany, means our investment in China will be larger, more sustained, and more committed. Our workforce has grown considerably this year and continues to grow," said Wang.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美日韩中文字幕一区 | 中字av在线 | 欧美性生交 | av不卡一区二区三区 | 99免费在线观看视频 | 超碰98在线观看 | 黄色网址av | 欧美片在线观看 | 免费在线中文字幕 | 超碰加勒比 | 日韩国产传媒 | 日韩精品国产一区 | 激情爱爱网 | 欧美大片高清免费观看 | 一级片一级片一级片 | 欧美高清a | 欧美日一区二区 | 国产欧美日韩在线观看 | 正在播放一区二区 | 精品一区二区三区四区 | 欧美一级网 | 青青综合网 | 久久综合一本 | 久久99精品久久久久久国产越南 | 综合欧美日韩 | 天天精品综合 | www免费网站在线观看 | 久久草视频在线 | 麻豆av一区 | 人人插人人搞 | 国产美女久久久久久 | 91色在线视频 | 午夜精品久久久久久久爽 | 第一福利av | 亚洲欧美日韩综合在线 | 久久黄色免费 | 色婷av | 欧产日产国产69 | 欧美aaa大片 | 五月综合久久 | 久久国产欧美 |